Open Terminal →

Analyses / MRNA

MRNA Moderna, Inc. As of Nov 19, 2026
$196.79

Large-cap biotech after a sharp 52-week drawdown. Revenue is contracting and losses are large. Event-driven read with limited fundamental data.

Setup: Event-driven recovery watch Confidence: low Horizon: 3m Risk: high Category: Large Cap (Biotechnology)
🔒 Trade Plan — entry · target · stop
Entry Zone
$•••–•••
Target
$•••
Stop Loss
$•••
Risk / Reward
•.• : 1
Unlock the exact levels — free →

A free account reveals MRNA's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.

The Thesis

▲ Bull Case

If the cancer therapy filing stays on its year-end timeline and the stock holds above the 196.52 day low, the setup could attract renewed interest. Current ratio of 3.29 gives balance-sheet liquidity room. Price-to-FCF of 17.5x is below what a stressed name might carry, and the stock sits about 30% under its 52-week high of 280.8. Stock reportedly rose on the cancer data before a sharp reversal, so sentiment could improve if the pipeline story gains traction.

▼ Bear Case

Revenue fell 53.44% and operating margin is -158.13%, so the business is shrinking while losing money. Insider activity skews to selling (150 sell vs 102 buy transactions; 3.59M shares sold vs 3.32M bought). Price-to-sales of 41.3x leaves little room for disappointment. Headlines show the stock fell despite positive cancer data, which may point to skepticism about commercial revenue. A break below the 196.52 day low opens a move toward the 52-week low zone.

Valuation

stretched on sales, unclear on earnings — score 35/100

Multiples that rely on earnings are null or negative. Price-to-sales is very high against a shrinking revenue base.

Technical Levels

Support · $196.52 (Today's day low) · $22.28 (52-week low (distant reference))

Resistance · $206.80 (Prev close / open) · $208.68 (Today's day high) · $280.80 (52-week high)

RSI: unavailable

Financial Health

Score 55/100. Liquidity ratios look comfortable. Leverage and coverage data are missing, so solvency cannot be fully assessed.

Catalysts

Cancer therapy regulatory filing (per headline, targeted by year-end)Year-end (per news headline)high
Market reaction to cancer vaccine data, which lifted results but drove the stock lowerRecent (per news)medium
Ongoing insider selling activityContinuous (per provider insider data)low

Risk Flags

Revenue growth -53.44% with operating margin -158.13% and net margin -145.16%.
P/E, forward P/E, ROE, ROIC and debt-to-equity are null in provider data.
Fundamentals, balance sheet, cash flow, sentiment and RSI fields are unavailable.
prevClose and open are both 206.80, so the prior-close reference may be stale.
EV/EBITDA is negative (-28.19), so the multiple is not meaningful here.
Insider activity is net selling: 150 sells vs 102 buys in provider data.

See MRNA's full trade plan — free

Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.

Unlock MRNA free →

Recent News

More Analyses

MRNA FAQ

Is MRNA a buy right now?

Moderna, Inc.'s current read is a Event-driven recovery watch setup with low confidence over a 3m horizon. Valuation: stretched on sales, unclear on earnings. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.

Is MRNA overvalued?

stretched on sales, unclear on earnings (valuation score 35/100). Multiples that rely on earnings are null or negative. Price-to-sales is very high against a shrinking revenue base.

What are the risks of buying MRNA?

Revenue fell 53.44% and operating margin is -158.13%, so the business is shrinking while losing money. Insider activity skews to selling (150 sell vs 102 buy transactions; 3.59M shares sold vs 3.32M bought). Price-to-sales of 41.3x leaves little room for disappointment. Headlines show the stock fell despite positive cancer data, which may point to skepticism about commercial revenue. A break below the 196.52 day low opens a move toward the 52-week low zone.